The firm will evaluate the combination therapy in 80 patients with germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer.
The VERVE-102 base editor appeared to be safe and reduce low-density lipoprotein cholesterol levels by up to 62 percent in a Phase 1 open-label, single-ascending dose trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results